Nelnet: Q3 Earnings Miss, Revenue Slides
Mini conglomerate Nelnet ( NNI -8.31%) released disappointing third-quarter results on Thursday, Nov. 7. The company reported adjusted EPS of $0.34, falling well short of the analyst consensus estimate of $1.36. Revenue also missed expectations, coming in at $237.3 million compared to the anticipated $340.16 million.
Fluor's Q3 Earnings & Revenues Miss Estimates, Guidance Lowered
Fluor reported adjusted earnings per share (EPS) of 51 cents, which missed the Zacks Consensus Estimate of 78 cents by 34.6%. The reported figure decreased 50% from an EPS of $1.02 a year ago. Fluor Corporation price-consensus-eps-surprise-chart | Fluor Corporation Quote Quarterly revenues of $4.
The healthcare diagnostics specialist exceeded top- and bottom-line expectations despite a slight revenue drop.
IT services company DXC Technology forecast current-quarter revenue and profit above Wall Street estimates on Thursday, ...
TruBridge, Inc. (NASDAQ:TBRG) Q3 2024 Earnings Call Transcript November 8, 2024 TruBridge, Inc. misses on earnings expectations. Reported EPS is $-0.21 EPS, expectations were $0.27. Operator: ...
Block’s Bitcoin revenue stagnated in the third quarter, and the fintech firm’s shares dropped by 12% after the bell as it ...
Tesla, Inc.'s Q3 earnings report and the presidential election outcome led me to upgrade my rating from SELL to HOLD. Explore ...
The Marin County developer of treatments for rare diseases noted that its treatment for a form of rickets has been driving ...
Q3 2024 Earnings Call Transcript November 8, 2024 PAR Technology Corporation beats earnings expectations. Reported EPS is $-0 ...
Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...
Poland's BNP Paribas BP posted a higher-than-expected 43% jump in third-quarter net profit on Friday, supported by strong ...
Iovance Biotherapeutics ( (IOVA)) has released its Q3 earnings. Here is a breakdown of the information Iovance Biotherapeutics presented to its investors. Iovance Biotherapeutics, Inc. is a ...
Monster Beverage recorded record net sales for Q3 2024 but faced profitability challenges due to increased expenses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback